ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, a meta-analysis showed that the benefits of second and third generation BCR-ABL TKIs in improving CML molecular remission are mitigated by the excess cardiovascular morbidity [6].